Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SARASOTA, Fla. — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE Ameri